Chemical Exchange Weighted Molecular MRI: Technical Development and Clinical Translation

TR&D1：化学交换加权分子MRI：技术开发和临床翻译 项目PI：Ravinder Reddy博士 摘要 该TR & D项目的重点是代谢物加权CEST MRI技术，用于空间分辨成像， 几种关键代谢物（谷氨酸、肌醇、肌酸和乳酸）可作为多种生物标志物， 疾病过程。为此，它开发了新技术，包括（i）B1的深度学习方法， 不同代谢物的CEST图像的B0校正（ii）用于改进空间的体积采集方法 不同代谢物的CEST加权成像的分辨率，以及（iii） 运动介导的骨骼肌OXPHOS测量，和（iv）CrCEST采集方法， 测量人心肌的代谢活性。这些技术由7个合作驱动， 服务8个服务项目，来自宾夕法尼亚州和分布在美国各地的其他机构。成功 实现这些目标将产生对生物医学领域产生持续影响的技术 通过他们对理解几种疾病的病理生理基础的贡献， 通过使用这些技术作为生物标志物，用于诊断和评价 现有的和新的疗法构成了患者护理的精确医学策略。此外，本发明还提供了一种方法， 将这些技术传播给来自PENN和国内外机构的合作者， 下一代生物医学科学家和医生科学家的培训，以及 这些技术的商业化将产生巨大的国家影响。

TR&D1: Chemical Exchange Weighted Molecular MRI: Technical Development and Clinical Translation Project PI: Ravinder Reddy, PhD Abstract This TR&D project focuses on metabolite weighted CEST MRI technologies for spatially resolved imaging of several key metabolites (glutamate, myoinositol, creatine and lactate) that serve as biomarkers of a variety of disease processes. To this end, it develops novel technologies including (i) deep learning approaches for B1 and B0 correction of CEST images of different metabolites (ii) volumetric acquisition methods for improved spatial resolution of the CEST weighted imaging of different metabolites and (iii) technologies for dynamic studies of exercise mediated OXPHOS measurements in skeletal muscle, and (iv) CrCEST acquisition methods for measuring the metabolic activity of human myocardium. These technologies are driven by 7 collaborations and serve 8 service projects from within PENN and from other institutions distributed across the US. Successful completion of the goals will lead to technologies that will have sustained impact on the field of biomedicine through their contribution to the understanding of pathophysiological underpinnings of several disorders, and through the use of these technologies as biomarkers for diagnosis and evaluation of therapeutic responses of existing and novel therapies that constitute precision medicine strategies for patient care. In addition, dissemination of these technologies to collaborators from PENN and institutions across the country and abroad, and training of next generation of biomedical scientist and physician scientists, and potential opportunities for commercialization of the technologies will have immense national impact.